Select Page

Avicanna reports Q2 2023 financial statement

Grow Opportunity, Media Partners

This post is presented by our media partner Grow Opportunity
View the full article here.

(Globe Newswire) Toronto — Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the filing of interim financial statements for the three-month period ending June 30, 2023.

“We are pleased to present the results of the second quarter and report the progress of our operations, which includes the increase in revenues and improvements in margins. During the quarter we worded towards the closing of the acquisition of the Medical Cannabis by Shoppers business and prepared for the launch of the new medical cannabis care platform,, and continued to make advancements in our Canadian operations with a focus on our proprietary medical products.” — Aras Azadian, CEO, Avicanna

Q2-2023 highlights:

Financial highlights: Q2 2023 revenue of $3.3 million, an increase of 183% over Q1 2023 and 200% over the comparable quarter which was mainly attributed to the takeover of certain operational responsibilities and sales-revenue rights related to acquisition of the Medical Cannabis by Shoppers business.  General and administrative expenses increased by 6% over the same period resulting in a 26% improvement in adjusted EBITDA over the comparable quarter of the prior year and an improvement of 18% over the first quarter of 2023.

Canadian commercial advancements: 26 commercial SKUs and 118 total commercial listings that resulted in a 120% growth in listings and 70% growth in finished goods sold compared to the comparable quarter 2022, with 43% gross margins in its North American operations compared to 20% gross margins in the comparable quarter 2022.


Medical Cannabis By Shoppers: On May 29, 2023, the Company announced that the definitive Asset Purchase Agreement with Shoppers Drug Mart Inc. for Avicanna to acquire the Medical Cannabis By Shoppers business was fully executed. On May 4, 2023, Avicanna announced the execution of the definitive Master Service Agreement with Northern Green Canada (NGC). NGC is a Canadian licensed producer that is tasked with providing logistics and fulfilment services for Avicanna’s cannabis care platform, On May 29, 2023, NGC and Avicanna successfully acquired the inventory for Medical Cannabis by Shoppers and transitioned inventory and fulfilment services to NGC.

Proprietary SEDDS Capsules: On June 25, 2023, Avicanna announced the expansion of the Strategic Manufacturing Agreement (SMA) with MediPharm Labs Corp. (MediPharm), adding the manufacturing and commercialization of company’s proprietary SEDDS capsules to the SMA. Avicanna’s proprietary SEDDS
capsules are to be manufactured by MediPharm to GPP and GMP standards to meet product channel requirements in Canadian and international markets. The capsules are expected to be launched under the RHO Phyto brand in Canadian medical cannabis channels during the second half of 2023.

New Medical Cannabis Education and Training Campaign and sponsorship of Canadian Consortium for the Investigation of Cannabinoids (CCIC). Through a Sponsorship Agreement, CCIC’s Canadian Cannabis Syllabus (CCS’) will be made available to the medical community. The CCS provides foundational information for healthcare professionals interested in learning more about cannabis and cannabinoid products in clinical practice.

Research Collaboration with Langara College and NSERC Grant. Through a Research Collaboration led by Dr. Jessica Kalra and Dr. Kalra’s research team, research will be conducted focusing on characterization of Avicanna’s proprietary products and drug pipeline formulations through in vitro and in vivo models. This Research Collaboration was awarded a two-year grant by the Natural Sciences and Engineering Research Council of Canada.

Other highlights subsequent to June 30, 2023:

Launch of is Avicanna’s medical cannabis care platform to serve the needs of medical cannabis patients. features diverse and scientifically curated products from leading Canadian licensed producers in addition to pharmacist-led patient support programs and educational resources to support the incorporation of medical cannabis into health care regimens. also provides specialty services to distinct patient groups such as veterans, and collaborating with public and private providers for adjudication and reimbursement. The platform is now available nationwide in Canada to tens of thousands
of patients who have obtained medical cannabis authorization from healthcare providers with an initial product portfolio including 35 brands and over 200 SKUs selected from various Canadian licensed producers

Closed acquisition of Medical Cannabis by Shoppers Drug Mart business. Avicanna acquired specific assets of the Medical Cannabis by Shoppers Drug Mart business, including inventory and equipment, for approximately $2.6M and will pay Shoppers Drug Mart an earnout, based on net revenues, for a period of two years. First launched in Ontario in January 2019, Medical Cannabis by Shoppers provided patients access to medical cannabis products from more than 30 licensed cannabis brands. Over the past four years, the legacy Medical Cannabis by Shoppers business supported tens of thousands of patients and worked with patient groups to facilitate access to medical cannabis.

This post was originally published by our media partner here.